There is empirical evidence that shows that depression shrinks several parts of the brain. These include the hippocampus, ...

Ketamine, a hallucinogenic drug approved as an anesthetic, has been used to treat adults with depression, PTSD and other ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Medically reviewed by Dakari Quimby, PhD Male postpartum depression describes when a new father experiences postpartum ...

Clinics offering ketamine infusions and injections for “treatment-resistant depression” are today claiming 24-48 hours ...

Discover why psychiatrists are moving beyond single-treatment approaches and how combining therapies could be the key to ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

H.C. Wainwright says that while Neumora Therapeutics ’ KOASTAL-1 result “was a surprise and disappointment,” the better results for female patients provide reason to remain ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Launched this year, Miami-based Hope Therapeutics is a developer of NRX-100, a ketamine drug used to treat suicidal ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...